Johnson Investment Counsel’s AbbVie ABBV Stock Holding History

Johnson Investment Counsel’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.1M	Sell	155,264 -2,946	-2%	-$634K	0.29%	83
2026 Q1	$34.4M	Buy	158,210 +1,104	+0.7%	+$245K	0.28%	87
2025 Q4	$35.9M	Sell	157,106 -1,629	-1%	-$371K	0.29%	83
2025 Q3	$36.8M	Buy	158,735 +2,209	+1%	+$450K	0.31%	80
2025 Q2	$29.1M	Sell	156,526 -5,298	-3%	-$985K	0.26%	85
2025 Q1	$33.9M	Buy	161,824 +5,356	+3%	+$1.04M	0.33%	75
2024 Q4	$27.8M	Buy	+156,468	New	+$28.8M	0.27%	80
2024 Q2	–	Sell	-152,158	Closed	-$27.7M	–	766
2024 Q1	$27.7M	Buy	+152,158	New	+$26.2M	0.3%	76
2023 Q3	–	Sell	-147,358	Closed	-$19.9M	–	679
2023 Q2	$19.9M	Buy	147,358 +2,017	+1%	+$296K	0.25%	78
2023 Q1	$23.2M	Sell	145,341 -655	-0.4%	-$100K	0.31%	75
2022 Q4	$23.6M	Sell	145,996 -4,218	-3%	-$647K	0.32%	76
2022 Q3	$20.2M	Buy	150,214 +3,899	+3%	+$560K	0.3%	76
2022 Q2	$22.4M	Buy	146,315 +32	+0%	+$4.89K	0.32%	76
2022 Q1	$23.7M	Buy	+146,283	New	+$21.2M	0.29%	78
2021 Q4	–	Sell	-143,483	Closed	-$15.5M	–	669
2021 Q3	$15.5M	Buy	143,483 +2,170	+2%	+$248K	0.21%	82
2021 Q2	$15.9M	Sell	141,313 -2,135	-1%	-$240K	0.22%	80
2021 Q1	$15.5M	Buy	143,448 +1,179	+0.8%	+$126K	0.23%	78
2020 Q4	$15.2M	Buy	142,269 +661	+0.5%	+$63.5K	0.25%	71
2020 Q3	$12.4M	Sell	141,608 -1,032	-0.7%	-$97.2K	0.23%	76
2020 Q2	$14M	Buy	+142,640	New	+$12.6M	0.28%	67
2020 Q1	–	Sell	-139,824	Closed	-$12.4M	–	525
2019 Q4	$12.4M	Sell	139,824 -2,031	-1%	-$169K	0.23%	82
2019 Q3	$10.7M	Sell	141,855 -1,421	-1%	-$97.4K	0.21%	85
2019 Q2	$10.4M	Sell	143,276 -115	-0.1%	-$9.04K	0.22%	88
2019 Q1	$11.6M	Buy	143,391 +1,502	+1%	+$123K	0.25%	85
2018 Q4	$13.1M	Sell	141,889 -3,133	-2%	-$276K	0.32%	75
2018 Q3	$13.7M	Sell	145,022 -860	-0.6%	-$81.6K	0.3%	74
2018 Q2	$13.5M	Buy	145,882 +10,894	+8%	+$1.06M	0.33%	73
2018 Q1	$12.8M	Sell	134,988 -156	-0.1%	-$17.1K	0.33%	71
2017 Q4	$13.1M	Sell	135,144 -461	-0.3%	-$43.4K	0.33%	73
2017 Q3	$12M	Buy	135,605 +878	+0.7%	+$66.8K	0.32%	75
2017 Q2	$9.77M	Sell	134,727 -4,384	-3%	-$295K	0.27%	78
2017 Q1	$9.06M	Sell	139,111 -12,011	-8%	-$755K	0.26%	78
2016 Q4	$9.46M	Sell	151,122 -442	-0.3%	-$27K	0.29%	77
2016 Q3	$9.56M	Buy	151,564 +1,090	+0.7%	+$70.6K	0.31%	74
2016 Q2	$9.31M	Sell	150,474 -5,884	-4%	-$359K	0.31%	73
2016 Q1	$8.93M	Buy	156,358 +23,712	+18%	+$1.32M	0.31%	67
2015 Q4	$7.86M	Buy	132,646 +2,666	+2%	+$154K	0.28%	75
2015 Q3	$7.07M	Sell	129,980 -61	-0%	-$3.97K	0.26%	84
2015 Q2	$8.74M	Buy	130,041 +700	+0.5%	+$45.7K	0.29%	75
2015 Q1	$7.57M	Sell	129,341 -2,588	-2%	-$156K	0.25%	83
2014 Q4	$8.63M	Sell	131,929 -1,893	-1%	-$119K	0.28%	77
2014 Q3	$7.73M	Buy	+133,822	New	+$7.43M	0.26%	77

Other funds holding ABBV

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

FWCM

Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return

Johnson Investment Counsel's ABBV Position: Q2 2026 in Review

Johnson Investment Counsel reduced its AbbVie (ABBV) stake by 1.9% in Q2 2026, selling an estimated $634K and leaving 155,264 shares worth $39.1M. The position accounts for 0.29% of the portfolio, ranked #83.

Johnson Investment Counsel first reported a position in ABBV in Q3 2014 and has held it in 42 quarters since. 1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Johnson Investment Counsel held 155,264 shares of AbbVie worth $39.1M as of Q2 2026.
Johnson Investment Counsel sold 2,946 AbbVie shares in Q2 2026, an estimated $634K.
AbbVie made up 0.29% of Johnson Investment Counsel's portfolio in Q2 2026, its #83 holding.
Johnson Investment Counsel first reported a position in AbbVie in Q3 2014 and has held it in 42 quarters since.
1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Johnson Investment Counsel's 13F filing for Q2 2026, filed 23 Jul 2026.